Raleukin (AMG-719) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin (AMG-719) is the first biological agent to block the pro-inflammatory effects^[1][2].

IL-1R^[1].

Combined Etanercept (5 mg/kg, ip) and Anakinra (100 mg/kg, ip. daily for 7 days) substantially improves marginal mass human islet engraftment in immunodeficient mice^[2].
Raleukin (AMG-719) enhances tumor growth inhibition in mice receiving peptide vaccination and β-(1-3),(1-6)-D-glucan^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

17257.60

C₇₅₉H₁₁₈₆N₂₀₈O₂₃₂S₁₀

143090-92-0

阿那白滞素

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Cvetkovic RS, et al. Anakinra. BioDrugs. 2002;16(4):303-11; discussion 313-4.

  [2]. McCall M, et al. Anakinra potentiates the protective effects of etanercept in transplantation of marginal mass human islets in immunodeficient mice. Am J Transplant. 2012 Feb;12(2):322-9.

  [3]. Harnack U, et al. IL-1 receptor antagonist anakinra enhances tumour growth inhibition in mice receiving peptide vaccination and beta-(1-3),(1-6)-D-glucan. Anticancer Res. 2010 Oct;30(10):3959-65.